Keppra (levetiracetam) works by binding to a protein called SV2A that sits on the surface of tiny sacs inside nerve cells, changing how those sacs release chemical signals. This mechanism is completely different from older seizure medications, which typically work by blocking electrical channels or boosting the brain’s natural braking signals. That unique approach is a big part of why Keppra has become one of the most widely prescribed seizure medications since its FDA approval in 2000.
The SV2A Protein and Why It Matters
To understand Keppra, you need to know a little about how nerve cells communicate. When a nerve cell fires, tiny bubble-like sacs called synaptic vesicles move to the cell’s edge and release chemical messengers into the gap between neurons. A protein called SV2A is embedded in the wall of these vesicles and helps regulate when and how they release their contents.
Keppra binds directly to SV2A. Research published in the Proceedings of the National Academy of Sciences confirmed this by studying mice that were genetically engineered to lack SV2A entirely. Brain tissue from those mice showed zero binding activity with the drug, proving SV2A is the essential target. Without SV2A, both excitatory and inhibitory signaling between neurons is reduced, and the mice themselves develop seizures.
That last detail is important because it reveals something surprising about Keppra’s mechanism. If SV2A helps release neurotransmitters and losing it causes seizures, you might expect that a drug binding to SV2A would also cause seizures. Instead, Keppra prevents them. Researchers believe the drug doesn’t simply block SV2A. It appears to fine-tune one of SV2A’s functions, specifically the ability to calm abnormal bursts of electrical activity in epileptic circuits. In other words, Keppra doesn’t shut the system down. It stabilizes it.
How This Differs From Other Seizure Medications
Most older anti-seizure drugs fall into a few familiar categories. Some block sodium channels, slowing down the rapid-fire electrical signals that drive seizures. Others enhance the effect of GABA, the brain’s primary calming chemical. A few target calcium channels. Keppra does none of these things. Its entire action centers on SV2A and the regulation of neurotransmitter release at the vesicle level, which is upstream of all those other mechanisms.
This distinction has practical consequences. Because Keppra works through a different pathway, it can be combined effectively with drugs that use those more traditional mechanisms. It’s also why Keppra’s side effect profile and drug interaction profile look different from older medications.
What Seizure Types Keppra Treats
Keppra is approved for three main categories of seizures. For focal (partial-onset) seizures, where abnormal activity starts in one area of the brain, it’s approved for adults and children as young as one month old. For myoclonic seizures, the brief, shock-like jerks common in juvenile myoclonic epilepsy, it’s approved for patients 12 and older. And for primary generalized tonic-clonic seizures, the classic convulsive type affecting the whole brain, it’s approved for patients five and older.
In the United States, Keppra was originally approved only as add-on therapy, meaning it was prescribed alongside another seizure medication. In Europe, it gained approval as a standalone treatment for focal seizures. Comparative trials have since shown that Keppra performs on par with older first-line medications for focal epilepsy, with tolerability that is at least equal to or better than those older options.
Why Keppra Rarely Interacts With Other Drugs
One of Keppra’s biggest practical advantages is its clean drug interaction profile. Most medications are broken down by a family of liver enzymes called cytochrome P450. Keppra largely bypasses this system. Only about 24% of each dose undergoes any metabolic breakdown at all, and that process doesn’t involve liver enzymes. The rest is cleared unchanged through the kidneys.
According to FDA labeling, Keppra neither inhibits nor competes for the liver enzymes that process most other drugs. Clinical studies have specifically tested it alongside common medications including blood thinners, heart medications, oral contraceptives, and other seizure drugs. None of these showed meaningful interactions. For people who take multiple medications, this is a significant benefit. Many older seizure drugs are notorious for speeding up or slowing down the metabolism of other prescriptions, sometimes requiring careful dose adjustments across an entire medication regimen.
Common and Behavioral Side Effects
The most frequently reported side effects of Keppra are drowsiness, fatigue, dizziness, and weakness, particularly when first starting the medication or increasing the dose. These tend to improve over the first few weeks as the body adjusts.
The side effect that gets the most attention, though, is behavioral change. In a study of 517 patients, about 10% developed some form of psychiatric side effect. The breakdown: 3.5% experienced aggressive behavior, 2.5% developed mood disturbances like depression or anxiety, 2.3% had emotional instability, and 1.2% experienced psychotic symptoms. Depression rates in clinical trials ranged from about 2% to 6% depending on the dose, compared to roughly 3% in people taking a placebo. These numbers mean the vast majority of people tolerate Keppra without significant mood changes, but the risk is real enough that you and the people close to you should be aware of it. Irritability and a short temper are the most commonly described behavioral shifts, sometimes called “Keppra rage” informally.
Keppra During Pregnancy
For women who need seizure control during pregnancy, the choice of medication matters enormously. Keppra has one of the most reassuring safety profiles in this group. Data from the large European EURAP registry found a major birth defect rate of about 2.5% with Keppra, which is essentially the same as the 2% to 3% background rate seen in women without epilepsy. Lamotrigine shows a similarly low rate at around 3.1%.
Compare that to some older medications: phenytoin carries a 5% to 9% risk, phenobarbital about 6% to 9%, and valproate nearly 10%. This safety data has made Keppra and lamotrigine the preferred options for managing epilepsy during pregnancy when medication is necessary.
Kidney Clearance and Dose Adjustments
Because Keppra is primarily cleared through the kidneys rather than the liver, kidney function is the main factor that determines whether dose adjustments are needed. People with reduced kidney function clear the drug more slowly, which can lead to higher blood levels and stronger side effects if the dose isn’t reduced accordingly. For people with normal kidney function, Keppra’s clearance is straightforward, and routine blood level monitoring isn’t typically required the way it is with older seizure medications like phenytoin or valproate. This makes the day-to-day experience of taking Keppra simpler, with fewer lab visits and less fine-tuning.